Efficacy endpoints
PsA
DISEASE
Overall BASDAI score improvements were greater with upadacitinib 15 mg versus placebo at weeks 12 and 24 in both studies and according to both criteria used to define axial involvement (Fig. Mean Change From Baseline in Overall BASDAI and Modified BASDAI (Excluding Question 3) Scores, and Proportion of Patients Achieving BASDAI50, at Weeks 12 and 24 From SELECT-PsA 1 (non-bDMARD-IR) and SELECT-PsA 2 (bDMARD-IR). Mean change from baseline in the overall BASDAI score (In both studies, greater improvements in ASDAS scores were observed with upadacitinib 15 mg versus placebo at weeks 12 and 24 according to both criteria used to define axial involvement (Fig. Mean Change From Baseline in ASDAS Scores, and Proportion of Patients Achieving ASDAS Inactive Disease (ID) and ASDAS Low Disease Activity (LDA), at Weeks 12 and 24 From SELECT-PsA 1 (non-bDMARD-IR) and SELECT-PsA 2 (bDMARD-IR). Mean change from baseline in ASDAS (CRP) scores at weeks 12 and 24 for PsA patients with axial involvement defined by investigator judgement alone or investigator judgement and PRO-based criteria treated with placebo, upadacitinib 15 mg QD, or adalimumab 40 mg EOW from SELECT-PsA 1 (Long-term assessment of BASDAI and ASDAS efficacy endpoints in PsA patients with axial involvement treated with upadacitinib 15 mg demonstrated that the clinical improvements observed at weeks 12 and 24 were maintained at week 56 in both studies based on both criteria (Supplementary Table S